Inventor · disambiguated record
Scott Wilhelm
Also filed as: WILHELM SCOTT · WILHELM SCOTT M · WILHELM SCOTT MCCLELLAND
15 granted patents·13 pending applications·196 citations·filing 1995–2018
94Inventor score
Top patents by PatentIndex Score
28 records- 0194US5789434ADerivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitorsBAYER AG·Filed 1995·Granted Aug 4, 1998·49 cites·10 claims
- 0288US5886022ASubstituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Mar 23, 1999·47 cites·16 claims
- 0382US8637553B2Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditionsBOYER STEPHEN·Filed 2004·Granted Jan 28, 2014·15 cites·16 claims
- 0481US8680124B2Treatment of cancers with acquired resistance to kit inhibitorsWILHELM SCOTT·Filed 2008·Granted Mar 25, 2014·5 cites·34 claims
- 0581US8329408B2Methods for prognosis and monitoring cancer therapyWILHELM SCOTT·Filed 2006·Granted Dec 11, 2012·2 cites·4 claims
- 0679US7384947B2Fused tricyclic heterocycles useful for treating hyper-proliferative disordersBAYER HEALTHCARE LLC·Filed 2006·Granted Jun 10, 2008·2 cites·5 claims
- 0777US5854277AThiophenebutanoic acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Dec 29, 1998·13 cites·14 claims
- 0873US5859047ASubstituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Jan 12, 1999·10 cites·16 claims
- 0971US5874473ASubstituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Feb 23, 1999·9 cites·16 claims
- 1070US7144885B2Fused tricyclic heterocycles useful for treating hyper-proliferative disordersBAYER PHARMACEUTICALS CORP·Filed 2003·Granted Dec 5, 2006·4 cites·26 claims
- 1169US8796250B2Diaryl ureas for diseases mediated by PDGFRWILHELM SCOTT·Filed 2004·Granted Aug 5, 2014·5 cites·55 claims
- 1267US2015018393A1Treatment of cancers with acquired resistance to kit inhibitorsBAYER HEALTHCARE LLC·Filed 2014·Application pending·0 cites
- 1367US2018311220A1Treatment of cancers with acquired resistance to kit inhibitorsBAYER HEALTHCARE LLC·Filed 2018·Application pending·0 cites
- 1465US5886043ASubstituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Mar 23, 1999·5 cites·16 claims
- 1565US2010173954A1Treatment of cancers having resistance to chemotherapeutic agentsBAYER HEALTHCARE LLC·Filed 2008·Application pending·0 cites
- 1663US2017165242A1Treatment of cancers with acquired resistance to kit inhibitorsBAYER HEALTHCARE LLC·Filed 2017·Application pending·0 cites
- 1760US6166082ASubstituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1998·Granted Dec 26, 2000·23 cites·18 claims
- 1859US5861427ASubstituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitorsFiled 1997·Granted Jan 19, 1999·4 cites·16 claims
- 1955US5861428ASubstituted 4-biarylbutyric acid derivatives as matrix metalloprotease inhibitorsBAYER AG·Filed 1997·Granted Jan 19, 1999·3 cites·16 claims
- 2055US2013131122A1Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and ConditionsBAYER HEALTHCARE LLC·Filed 2012·Application pending·0 cites
- 2155US2010144749A1Treatment of cancers with acquired resistance to kit inhibitorsWILHELM SCOTT·Filed 2006·Application pending·0 cites
- 2254US2009068146A1Diaryl ureas and combinationsWILHELM SCOTT·Filed 2006·Application pending·0 cites
- 2353US2017172989A1Treatment of cancers having resistance to chemotherapeutic agentsBAYER HEALTHCARE LLC·Filed 2017·Application pending·0 cites
- 2452US2009215835A1Treatment of cancer with sorafenibWILHELM SCOTT·Filed 2006·Application pending·0 cites
- 2549US2013012550A1Methods for prognosis and monitoring cancer therapyBAYER HEALTHCARE LLC·Filed 2012·Application pending·0 cites
- 2646US2007178494A1Methods for prediction and prognosis of cancer, and monitoring cancer therapyELTING JAMES·Filed 2006·Application pending·0 cites
- 2745US2016279113A1Treatment of cancer with sorafenibBAYER HEALTHCARE LLC·Filed 2016·Application pending·0 cites
- 2845US2007292887A1Immunohistochemical MethodsBAYER PHARMACEUTICALS CORP·Filed 2004·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →